alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › benefits

benefits

2 studies tagged benefits, dated 2018-11-01 to 2019-08-24. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Media Coverage of the Benefits and Harms of Testing the Healthy: a protocol for a descriptive study 2019-08-24
  2. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease 2018-11-01

Studies

2 studies carry this tag.

Date range

2018 to 2019

Top journals

  • BMJ open 1
  • Scientific reports 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Media Coverage of the Benefits and Harms of Testing the Healthy: a protocol for a descriptive study

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. BMJ open 2019-08-24 Biomarkers

    Much testing in medicine is aimed at healthy people to facilitate the early detection of health conditions.

  2. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Scientific reports 2018-11-01 Brain scans and imaging

    Accumulation of alpha-synuclein (ASYN) in neurons and other CNS cell types may contribute to the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA).

All topic tags with their study counts